Urea Cycle Disorders Treatment Market Worth US$ 1,510.2 Million With a CAGR of 16.8% By 2028 | Bausch Health Companies, Inc., Recordati Rare Diseases Inc., Lucane Pharma SA, Acer Therapeutics,

Global Urea Cycle Disorders Treatment Market

Global Urea Cycle Disorders Treatment Market had a valuation of US$ 1,188.9 million in 2020 and is anticipated to grow at a CAGR of 3.5% over the estimated timeframe (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The increasing number of pipeline items for the treatment of urea cycle issues is projected to fuel the development of the global urea cycle disorders treatment market.

On September 17, 2019, Kaleido Biosciences, a clinical-stage medical organization, started a stage 2 clinical preliminary review to assess the viability and security of KB195 in subjects with urea cycle problems with extreme indications. The review is estimated to be finished in November 2021.

Request Here Free Sample Report

Effect of the COVID-19 Pandemic

The COVID-19 pandemic caused significant disturbances in the execution of clinical preliminaries in the U.S., affecting key partners across the global urea cycle disorders treatment market. During the pandemic, insightful site abilities experienced commotion, which was driven by staff vacations, social-separating conventions, monetary misfortunes, and worries over tolerant wellbeing. Backers, CROs, and different associations that help drug improvement move to remote workplaces. An expected 80% of non-COVID-19 preliminary tests were halted or hindered due to the COVID-19 pandemic.

According to an April 2020 review, analytical destinations demonstrate adaptability and resourcefulness in adopting new methodologies to adapt to challenges introduced by the COVID, with a large portion of insightful locales progressing to virtual methods to deal with patient interfaces. A couple of follow-up investigations were performed on COVID-19 in August 2020, recognizing the relentless effect of COVID on clinical preliminaries, with more than 60% announcing a normal or more prominent degree of effect of COVID on the continuous clinical preliminaries as well as in the commencement of new preliminaries. Respondents explicitly featured the difficulties in quiet enlistment and enrollment due to the COVID-19 pandemic.

As of late, the U.S. FDA direction (March 2020 and refreshed July 2020) recognized that the effect of COVID-19 might require organizations leading clinical preliminaries to think about virtual patient visits. Accordingly, presently there are more open doors for utilizing far-off medical services, including directing virtual or decentralized preliminaries, site-less clinical preliminaries, and utilization of other forward-thinking approaches that don’t affect face-to-face visits.

Also, different exploration organizations are zeroing in on understanding the effect of COVID-19 on patients experiencing acquired metabolic illnesses such as urea cycle issues. In January 2021, University Hospital, Lille started an observational review on the effect of COVID-19 on the balance of innate metabolic illness in patients with COVID-19 disease. The review is estimated to be finished by January 2023.

The global urea cycle disorders treatment market is estimated to offer a worthwhile open door sooner rather than later, attributable to the focal point of significant market players on inorganic development techniques like acquisitions, associations, and arrangements to reinforce their item portfolio and presence in the worldwide market.

In January 2021, Acer Therapeutics and RELIEF THERAPEUTICS Holding AG, a biopharmaceutical organization, entered into cooperation and permitted understanding for the overall turn of events and commercialization of acer-001, a sodium phenylbutyrate drug form for the treatment of urea cycle problems.

Request Here PDF Report

Key Takeaways

The global urea cycle disorders treatment market is anticipated to grow at a CAGR of 3.5% during the conjecture timeframe, inferable from key organizations zeroing in on innovative work for the therapy of disease.

Sodium phenylbutyrate is expected to hold a significant share of the global urea cycle disorders treatment market during the estimated timeframe, as evidenced by various organizations focusing on innovative work in urea cycle issues treatment.

Among compound inadequacy types, the OTC-Ornithine Transcarbamylase section is assessed to hold a significant portion of the global urea cycle disorders treatment market during the gauge time frame, inferable from different vital participants zeroing in on innovative work for the treatment of OTC-Ornithine Transcarbamylase lack.

Among the types of organization, oral fragments are assessed to hold a significant share in the global urea cycle disorders treatment market during the conjecture time frame, attributable to key players zeroing in on innovative work of orally directed medications such as Glycerol Phenylbutyrate for treatment of urea cycle problems.

Among the distribution channels, hospital drug stores are assessed to hold a significant share in the global urea cycle disorders treatment market during the estimated time frame, inferable from their central parts zeroing in on directing unique mindfulness programs and monetary help programs for treatment of urea cycle issues through medical care offices.

Major companies contributing to the global urea cycle disorders treatment market include Arcturus Therapeutics Holdings Inc., Aeglea BioTherapeutics, Acer Therapeutics, Lucane Pharma SA, NESTLÉ S.A., Bausch Health Companies, Inc., Mead Johnson & Company, LLC, Recordati Rare Diseases Inc., Danone S.A., Abbott Laboratories, Ultragenyx Pharmaceutical Inc., Selecta Biosciences, Inc., and Orpharma Pty Ltd.

Buy This Complete A Business Report

Table of Contents

1. Research Objectives and Assumptions
   • Research Objectives
   • Assumptions
   • Abbreviations
2. Market Purview
   • Report Description
     • Market Definition and Scope
   • Executive Summary
     • Market Snapshot, By Treatment Type
     • Market Snapshot, By Enzyme Deficiency Type
     • Market Snapshot, By Route of Administration
     • Market Snapshot, By Distribution Channel
     • Market Snapshot, By Region
   • Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
   • Drivers
   • Restraints
   • Opportunities
   • Impact Analysis
   • Key Developments
   • Treatment Approaches
   • Novel Therapies Under Development for the Treatment of UCD
   • Mergers, Collaborations, Acquisitions & Agreements
   • Pipeline Analysis
   • Regulatory Scenario
   • PEST Analysis
   • Product Approvals
   • Market Trends
   • Epidemiology
   • Therapeutics Overview
   • Brand Analysis
   • Reimbursement Scenario
   • Prescription Overview
4. Global Urea Cycle Disorders Treatment Market, Impact of COVID-19 Pandemic
   • COVID-19 Impact on Overall Healthcare Sector
   • COVID-19 Epidemiology
   • Impact of COVID-19 Impact on Supply Chain
   • Covid-19 Impact on Clinical Trials and Drug Development
5. Global Urea Cycle Disorders Treatment Market, By Treatment Type, 2016-2027 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017–2027
     • Segment Trends
       • Amino Acid Supplements
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • Sodium Phenylbutyrate
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • Glycerol Phenylbutyrate
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • Sodium Benzoate
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • Others (Low Protein Diet, Carglumic acid, etc.)
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
6. Global Urea Cycle Disorders Treatment  Market, By Enzyme Deficiency Type, 2016-2027 (US$ Mn)
   • Introduction
   • Market Share Analysis, 2020 and 2027 (%)
   • Y-o-Y Growth Analysis, 2017–2027
   • Segment Trends
     • • OTC – Ornithine Transcarbamylase
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • AS – Argininosuccinate Synthetase (citrullinemia)
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • AG – Arginase
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • AL – Argininosuccinate Lyase
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • CPS1 – Carbamoyl Phosphate Synthase
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • NAGS – N-acetylglutamate Synthase
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
7. Global Urea Cycle Disorders Treatment Market, By Route of Administration, 2016–2027 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017–2027
     • Segment Trends
       • Oral
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • Injectable
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
8. Global Urea Cycle Disorders Treatment Market, By Distribution Channel, 2016–2027 (US$ Mn)
   • Introduction
     • Market Share Analysis, 2020 and 2027 (%)
     • Y-o-Y Growth Analysis, 2017–2027
     • Segment Trends
       • Hospital Pharmacies
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • Retail Pharmacies
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)
       • Online Pharmacies
         • Introduction
         • Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Mn)

View Press Release